60' ROUNDTABLE – Should we really use new targeted inhibitors as single agents ?
Chair: Christoph Röllig (Dresden)
20' Next-generation FLT3 inhibitors Alexander Perl (Philadelphia)
20' The role of IDH1/2 inhibitors as monotherapy Courtney DiNardo (Houston)
20' Discussion
www.esh.org - info@esh.org 3
Mentored Poster Walks
60' 3 Simultaneous Meet the Expert sessions
1. CNS prophylaxis and treatment in ALL Wendy Stock (Chicago)
2. MRD as a treatment-stratifying tool in AML Sylvie Freeman (Birmingham)
3. Acute leukaemia and pregnancy Nicolas Boissel (Paris)
95' Addition of a 3rd agent to frontline 7+3
Chair : Andrew Wei (Melbourne)
20' Case-based lecture : Jorge Sierra (Barcelona)
Midostaurin
20' Case-based lecture : Juliette Lambert (Versailles)
Addition of gemtuzumab ozogamicin to front line 3+7 chemotherapy
20' Case-based lecture : Nigel Russell (Nottingham)
Nucleoside analogues in high-risk AML
Brief oral communication
5' Updated results from a phase 1 study of Gilteritinib in Alexander Perl (Philadelphia)
combination with induction and consolidation chemotherapy
in patients with newly diagnosed AML
30' Panel discussion
65' ROUNDTABLE – Curative options for older AML
Chair: Alexander Perl (Philadelphia)
15' Current intensive therapy of older AML patients in 2020 Thorsten Braun (Bobigny)
15' Liposomal daunorubicin/cytarabine Jorge E. Cortes (Augusta)
15' Defining the role of Venetoclax in older patients with AML Andrew Wei (Melbourne)
20' Discussion
20' INTERACTIVE CASES 2
Chair: Arnold Ganser (Hannover)
7' Management of high WBC APL Pau Montesinos (Valencia)
3' Discussion
SCIENTIFIC
PROGRAMME
RARE SUBSETS OF
ACUTE LEUKAEMIA
TRACKING LEUKAEMIC
STEM CELLS (LSCs)
ROUTINE DIAGNOSIS
GENE EXPRESSION
AND MUTATIONAL
PROFILING
DEBATE 1 – ALL
PATIENTS WITH
INTERMEDIATE-RISK
AML MUST BE
TRANSPLANTED
INTERACTIVE
CASES 1 – MUTATION-BASED
THERAPY
OFF-LABEL
ROUNDTABLE –
SHOULD WE REALLY
USE NEW TARGETED
INHIBITORS AS SINGLE
AGENTS ?
ADDITION OF A 3RD
AGENT TO FRONTLINE
7+3
ROUNDTABLE –
CURATIVE OPTIONS
FOR OLDER AML
INTERACTIVE CASES 2
DEBATE 2 - BEST
TREATMENT FOR
NPM1-MUTATED AML IN
THE NEXT FUTURE ?
ALLOGENEIC
HAEMATOPOIETIC
STEM CELL
TRANSPLANTATION
(HSCT)
IMMUNOTHERAPY FOR
ACUTE LEUKAEMIA
DEBATE 3 - T-ALL:
WHERE ARE WE GOING
NOW?
SELECTED ABSTRACTS
AND CLINICAL
CASES FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
FOR A POSTER
PRESENTATION
DISCLOSURES